Clinical Appreciation of LHRH Analogue Formulations

A. Lemay, Lemay A
Hormone research · 2008 · vol. 32(1) , pp. 93–102 · doi:10.1159/000181319 · PMID:2533161 · W2022369921
article OA: closed CC0 ⤵ 7 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-10 ⓘ

LHRH analogue formulations vary in their ability to inhibit the pituitary-ovarian axis and induce amenorrhea, with slow-release versions causing more severe estrogen deprivation symptoms but no significant changes in cholesterol or long-term bone density loss.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Luteinising hormone-releasing hormone (LHRH) analogues administered by a continuous release system produce a more complete and constant inhibition of the pituitary-ovarian axis than do multiple, daily intranasal insufflations or a once daily subcutaneous injection. In the present study, results were too limited to make a valid comparison between the clinical efficacy of various formulations in the treatment of endometriosis. A slow-release formulation is more effective in inducing amenorrhoea, but also produces more frequent and more severe clinical symptoms of oestrogen deprivation. There is no significant change in serum cholesterol levels during 6 months of treatment with any of the formulations used. During LHRH analogue treatment, the increase in urinary excretion of calcium is related to the rate and degree of serum oestradiol inhibition but the loss in bone mineral content is small and reversible after cessation of treatment. Both short-term and long-term treatment with LHRH analogues is feasible.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Endometriosis Gonadotropin-Releasing Hormone Buserelin Buserelin Buserelin Delayed-Action Preparations Endometriosis Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Goserelin Humans Leuprolide Nafarelin Triptorelin Pamoate

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (7)

Source provenance

europepmc
last seen: 2026-09-11T06:15:56.568227+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:15.954262+00:00
unpaywall
last seen: 2026-09-11T06:32:28.951138+00:00
License: CC0 · commercial use OK